|
 |
|||||||
 |
FAQs INVESTOR FREQUENTLY ASKED QUESTIONS Q: What is the Company's mission? A: Our mission is to introduce new technologies for anticancer and antiviral treatments that improve the performance and safety of existing drugs and address significant problems such as drug metabolism, toxicity, bioavailability and resistance. Q: What products does ADVENTRX have in development? A: We focus on the development of new therapies for cancer and HIV. Our lead product is CoFactor, an anticancer compound which is designed to improve the performance and safety of a widely used chemotherapeutic, 5-fluorouracil. Additional products for cancer and HIV are in preclinical development. To learn more about our other anticancer products, visit www.adventrx.com/products/cancer.htm. To learn more about our anti-HIV products in development, visit www.adventrx.com/products/candidates.htm. Q: When was the Company founded? A: We incorporated in the State of Delaware in December 1995 and began operations in 1996. We initially incorporated under the name "Victoria Enterprises, Inc." We subsequently changed our name to "BioQuest, Inc." then "Biokeys Pharmaceuticals, Inc." and finally "ADVENTRX Pharmaceuticals, Inc." in May 2003. Q: When did the Company go public? A: We initially registered our common stock pursuant to a Form 10SB first filed with the SEC in October 2001. We registered our common stock again on Form 8-A in April 2004. Q: Where is ADVENTRX located? A: We are located in the Sorrento Mesa area of San Diego, California. ADVENTRX Pharmaceuticals, Inc.Q: Where do the Company's shares trade? A: Our common stock trades on the American Stock Exchange (Amex) under the symbol ANX. Q: How many shares are currently outstanding? A: As of July 31, 2005 we had 66,028,312 shares of common stock outstanding. Q: Who is the Company's stock transfer agent? A: American Stock Transfer & Trust Company is our stock transfer agent and it maintains all our shareholder records. If you have questions regarding ADVENTRX stock you own, stock transfers, address or name changes, lost stock certificates, or duplicate mailings, please contact American Stock Transfer & Trust Transfer Company directly. If your shares are held with a stockbroker, please contact your broker. American Stock Transfer & Trust CompanyQ: What is the CUSIP Number of your common stock? A: The CUSIP Number for our common stock is 00764X103. Q: Does the Company issue dividends? A: We have never declared or paid a cash dividend on our capital stock. We currently intend to retain any earnings to fund the growth and development of our business. We do not anticipate paying any cash dividends in the foreseeable future. Q: Does the Company offer a direct stock purchase program? A: We do not offer a stock purchase program. Investors interested in buying ADVENTRX shares should contact their stockbroker. Q: What is the Company's fiscal year end? A: Our fiscal year ends on December 31. Q: Who are the Company's independent auditors? A: JH Cohn LLP. Q: Who is the Company's general outside corporate legal counsel? A: Bingham McCutchen LLP. Q: When is the next annual shareholder meeting? A: We currently plan to hold our next annual shareholder meeting in the first half of 2006, at a date and time to be named later. Q: How can I receive ADVENTRX Pharmaceuticals' updates? A: Simply contact us at ir@adventrx.com, or call 858 552-0866, give us your name, address or email address and request to be added to our distribution list to receive Company news. |
